Isofol appoints Petter Segelman Lindqvist as new CEO
GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company’s Board of […]
MAR
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects
GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received
Isofol has received the first results from laboratory tests of arfolitixorin
GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received
Isofol’s Board of Directors appoints Roger Tell as acting CEO of the company
Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has decided to
CEO resigns at his own request in Isofol Medical AB (publ)
Gothenburg, Sweden, June 21, 2023 – Isofol Medical AB (publ) announces today that Thomas Andersson, at his own request, has
Isofol’s board appoints Thomas Andersson as new CEO of the company
Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the board of Isofol
Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company
GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today to call an extraordinary general
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr.
Isofol provides update on the AGENT study
GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to
Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the